Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy of D9421-C 9 mg once daily
compared to Mesalazine 1 g three times a day to patients with mild to moderate active Crohn's
disease affecting ileum, ileocecal region and/or ascending colon as defined by a score of
180-400 on the Crohn's Disease Activity Index (CDAI) by assessment of the remission after
8-week treatment defined by a CDAI score of ≤ 150.